Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination (NCT04868877)
Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
Who can join: Review the eligibility criteria below.
Location: University of California, Irvine — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (51 Sites)
Showing the first 25 of 51 sites.
- University of California, Irvine — Orange, California
- Sarah Cannon Research Institute — Nashville, Tennessee
- START Mountain Region — West Valley City, Utah
- Next Oncology Virginia — Fairfax, Virginia
- Institut Jules Bordet — Anderlecht,
- Antwerp University Hospital — Edegem,
- Clinique de l'Europe — Amiens,
- CHU Hopitaux de Bordeaux - Hôpital Saint-André — Bordeaux,
- CHU de Lyon - Louis Pradel Hospital — Bron,
- Centre Hospitalier Intercommunal de Créteil — Créteil,
- Hôpital Albert Calmette — Lille,
- L'Institut Paoli - Calmettes — Marseille,
- CHU de Nantes - Hôpital Nord Laennec — Nantes,
- Marie Wislez — Paris,
- Hôpital Bichat - Claude-Bernard — Paris,
- Hôpital Européen Georges Pompidou (HEGP) — Paris,
- CHU de Poitiers — Poitiers,
- Hôpital d'Instruction des Armées Bégin — Saint-Mandé,
- Krankenhaus Nordwest — Frankfurt am Main, Hesse
- Sana Klinikum Offenbach GmbH — Offenbach,
- Istituto Nazionale dei Tumori Regina Elena — Roma, Rome
- Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi — Bologna,
- ASST degli Spedali Civili di Brescia — Brescia,
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan,
- ASST Grande Ospedale Metropolitano Niguarda — Milan,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer Metastatic
- Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer — Iowa City, Iowa
- HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer — Gilbert, Arizona
Explore by condition: All Non-Small Cell Lung Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.